Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...

“Agencies are no longer going to promote gender ideology through communication forms and other messages,” the official ... transgender have options in the Social Security number card application ...

The new Homeland Security secretary undid the Biden administration's extension of Temporary Protected Status on Wednesday.

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors$15 ...

Patel, Trump’s nominee to be FBI director, was paid $25,000 last year by a film company that has promoted anti-Western views ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...

Attorneys and advocacy organizations are navigating an increase in federal immigration arrests — and rampant rumors and misinformation.

These centers assist students with filling out financial aid forms, referrals to nonprofit immigration law ... at Los Angeles ...

Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB ...

FINRA issued its 2025 Annual Regulatory Oversight Report, providing a detailed look into FINRA’s current regulatory oversight ...

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing ...